HK1247847A1 - 四氫-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的對映體(ANAVEX2-73)及其在治療阿爾海默氏病和其他由σ1受體調節的疾病中的用途 - Google Patents
四氫-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的對映體(ANAVEX2-73)及其在治療阿爾海默氏病和其他由σ1受體調節的疾病中的用途Info
- Publication number
- HK1247847A1 HK1247847A1 HK18107442.9A HK18107442A HK1247847A1 HK 1247847 A1 HK1247847 A1 HK 1247847A1 HK 18107442 A HK18107442 A HK 18107442A HK 1247847 A1 HK1247847 A1 HK 1247847A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- anavex2
- furanmethanamine
- enantiomers
- tetrahydro
- alzheimer
- Prior art date
Links
- BOTHKNZTGGXFEQ-UHFFFAOYSA-N 1-(2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine Chemical compound CN(C)CC1CCOC1(C=1C=CC=CC=1)C1=CC=CC=C1 BOTHKNZTGGXFEQ-UHFFFAOYSA-N 0.000 title 1
- FEQOLYDPQKHFTD-UHFFFAOYSA-N 1-(2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine;hydrochloride Chemical compound Cl.CN(C)CC1CCOC1(C=1C=CC=CC=1)C1=CC=CC=C1 FEQOLYDPQKHFTD-UHFFFAOYSA-N 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 title 1
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195417P | 2015-07-22 | 2015-07-22 | |
| PCT/IB2016/001158 WO2017013496A1 (en) | 2015-07-22 | 2016-07-19 | Enantiomers of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine (anavex2-73) and use thereof in the treatment of alzheimer's disease and other disorders modulated by the sigma 1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1247847A1 true HK1247847A1 (zh) | 2018-10-05 |
Family
ID=57834974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18107442.9A HK1247847A1 (zh) | 2015-07-22 | 2018-06-07 | 四氫-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的對映體(ANAVEX2-73)及其在治療阿爾海默氏病和其他由σ1受體調節的疾病中的用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11617734B2 (zh) |
| EP (1) | EP3324956A4 (zh) |
| JP (3) | JP7429942B2 (zh) |
| CN (2) | CN116687906A (zh) |
| CA (1) | CA2986345A1 (zh) |
| HK (1) | HK1247847A1 (zh) |
| WO (1) | WO2017013496A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7304043B2 (ja) | 2015-07-22 | 2023-07-06 | アナベックス ライフ サイエンシズ コーポレイション | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物 |
| JP7180673B2 (ja) * | 2017-11-28 | 2022-11-30 | アナベックス ライフ サイエンス コーポレイション | シグマ－１受容体アゴニスト収縮期血圧療法 |
| CN112105349A (zh) * | 2018-04-12 | 2020-12-18 | 阿纳韦克斯生命科学公司 | A2-73结晶多晶型物质组合物及其使用方法 |
| JP2021524741A (ja) * | 2018-05-18 | 2021-09-16 | アナベックス ライフ サイエンス コーポレイション | レスポンダ選択および治療の最適化されたｓｉｇｍａ−１アゴニスト方法 |
| WO2021158586A1 (en) | 2020-02-04 | 2021-08-12 | Teva Pharmaceuticals International Gmbh | Solid state forms of blarcamesine salts |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2636625B1 (fr) | 1988-09-01 | 1990-11-09 | Jouveinal Sa | Benzylamines disubstituees, leur procede de preparation, leur utilisation comme medicament et leurs intermediaires de synthese |
| GR1002616B (el) * | 1996-02-21 | 1997-02-20 | Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης. | |
| US20110206780A1 (en) | 2010-01-06 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Morphinan modulators of nmda receptors, sigma1 receptors, sigma2 receptors, and/or a3b4 nicotinic receptors |
| GR1007686B (el) | 2011-07-08 | 2012-09-12 | Αλεξανδρος Δημητριου Βαμβακιδης | Συνθεση των (+) και (-) 1-(5,5-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης, (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης και (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν-μεθυλομεθυλαμινης |
| US20140378460A1 (en) * | 2011-08-25 | 2014-12-25 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
| FR2983732B1 (fr) * | 2011-12-09 | 2013-11-22 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent |
| GR1008233B (el) * | 2013-03-28 | 2014-06-23 | Αλεξανδρος Δημητριου Βαμβακιδης | Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες |
-
2016
- 2016-07-19 EP EP16827322.5A patent/EP3324956A4/en active Pending
- 2016-07-19 CN CN202310897135.1A patent/CN116687906A/zh active Pending
- 2016-07-19 JP JP2017564725A patent/JP7429942B2/ja active Active
- 2016-07-19 CA CA2986345A patent/CA2986345A1/en active Pending
- 2016-07-19 US US15/579,696 patent/US11617734B2/en active Active
- 2016-07-19 CN CN201680033151.4A patent/CN107708687A/zh active Pending
- 2016-07-19 WO PCT/IB2016/001158 patent/WO2017013496A1/en active Application Filing
-
2018
- 2018-06-07 HK HK18107442.9A patent/HK1247847A1/zh unknown
-
2021
- 2021-07-01 JP JP2021110038A patent/JP2021152077A/ja active Pending
-
2022
- 2022-10-04 US US17/959,920 patent/US20230044710A1/en active Pending
-
2023
- 2023-03-28 JP JP2023051980A patent/JP2023073373A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180169059A1 (en) | 2018-06-21 |
| JP2018524306A (ja) | 2018-08-30 |
| JP7429942B2 (ja) | 2024-02-09 |
| CN107708687A (zh) | 2018-02-16 |
| CA2986345A1 (en) | 2017-01-26 |
| US11617734B2 (en) | 2023-04-04 |
| EP3324956A1 (en) | 2018-05-30 |
| JP2023073373A (ja) | 2023-05-25 |
| CN116687906A (zh) | 2023-09-05 |
| US20230044710A1 (en) | 2023-02-09 |
| WO2017013496A1 (en) | 2017-01-26 |
| JP2021152077A (ja) | 2021-09-30 |
| EP3324956A4 (en) | 2019-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280530A (en) | Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease | |
| HRP20210518T1 (hr) | Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava | |
| HK1247847A1 (zh) | 四氫-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的對映體(ANAVEX2-73)及其在治療阿爾海默氏病和其他由σ1受體調節的疾病中的用途 | |
| EP3377118A4 (en) | METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
| WO2015143447A3 (en) | Methods for treating neurological disorders | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| GB2542155B (en) | Use of cannabidiol in the treatment of mental disorders | |
| HK1216641A1 (zh) | 用於治療σ受體相關疾病和病症的 -三唑- -胺 | |
| HK1258884A1 (zh) | 用於治療竇疾病和病症的組合物和方法 | |
| PL3634957T3 (pl) | Modulatory receptora NMDA, zawierające je kompozycje oraz zastosowanie tych związków w leczeniu chorób ośrodkowego układu nerwowego | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| IL260009B (en) | Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| 도진국 | Painful cranial neuropathies and facial pain | |
| GB201518052D0 (en) | Parkinson's disease treatment | |
| HUE046759T2 (hu) | 3Alfa-etinil, 3béta-hidroxi-5alfa-pregnán-20-oxim központi idegrendszeri rendellenességek kezelésében történõ alkalmazásra | |
| AU2015904411A0 (en) | Compositions and methods for the treatment of Alzheimer's disease |